Gyre Therapeutics
GYRE
65 hedge funds and large institutions have $59.3M invested in Gyre Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 15 closing their positions.
38% more call options, than puts
Call options by funds: $554K | Put options by funds: $401K
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.48% less ownership
Funds ownership: 8.87% → 8.39% (-0.48%)
7% less funds holding
Funds holding: 70 → 65 (-5)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
31% less capital invested
Capital invested by funds: $85.6M → $59.3M (-$26.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$8.41M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$2.26M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.01M |
| 4 |
2L
22NW LP
Seattle,
Washington
|
+$1.4M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$5.08M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$3.45M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.05M |
| 4 |
SCM
Sio Capital Management
New York
|
-$2.55M |
| 5 |
Renaissance Technologies
New York
|
-$2.38M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
76
Tower Research Capital (TRC)
New York
| – | -$10K | -124 | Closed |
|
77
Group One Trading
Chicago,
Illinois
| – | -$8.33K | -113 | Closed |
|
78
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -31 | Closed |
|
79
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$2K | -23 | Closed |
|
GYRE Hedge Fund Activity: Q4 2018 in Review
65 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2018, worth a combined $59.3M — down 31% from $85.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of GYRE and 11 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 24 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $8.41M. The largest seller was Nexthera Capital, cutting an estimated $5.08M.
- 65 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2018, down from 70 in Q3 2018.
- Funds reported $59.3M of Gyre Therapeutics stock for Q4 2018, down 31% quarter-over-quarter.
- 11 funds opened new Gyre Therapeutics positions in Q4 2018 and 15 closed out, a net change of -4 holders.
- The largest Gyre Therapeutics buyer in Q4 2018 was Nantahala Capital Management, an estimated $8.41M added.
- The largest Gyre Therapeutics seller in Q4 2018 was Nexthera Capital, an estimated $5.08M sold.
Based on aggregated 13F filings for Q4 2018.